Project Grant R01HL177696
Award Date 8/4/26
Completion Date 4/30/30
Dollars Obligated $778K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Hershey, PA 17033, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Pennsylvania State University, operating as Penn State Milton S. Hershey Medical Center, $105,705 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on surfactant protein-A (SP-A) variants and their role in regulating lung innate immunity. The research aims to elucidate molecular mechanisms by which SP-A variants regulate innate immune responses in the lung, with applications to acute and...
- The National Heart, Lung, and Blood Institute awarded $1,137,435 to the University of Pennsylvania on March 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to advance therapeutic gene-editing approaches for cardiovascular and inherited disease. The recipient is developing and translating gene-editing therapies across three therapeutic domains. The first targets liver-centered, multiplex editing to prevent atherosclerotic cardiovascular disease through tunable...
- The National Heart, Lung, and Blood Institute awarded $799,998 to The Trustees of the University of Pennsylvania on August 12, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop cardiotropic solid lipid nanoparticles (LNPs) as a drug and biologic delivery platform for cardiac therapeutics. The research focuses on engineering and understanding heart-targeting LNPs that accumulate in cardiac tissue at significantly higher concentrations than existing drug delivery...
- The National Heart Lung and Blood Institute awarded the University of Pennsylvania $169,020 on April 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the genomic and clinical mechanisms of myocardial lipomatous metaplasia and its prognostic implications for cardiac dysfunction and arrhythmia. The recipient will apply a deep-learning segmentation model to cardiac CT images from the Penn Medicine Biobank (23,940 participants with genotypes and imaging as of...
- The National Heart, Lung, and Blood Institute awarded Pennsylvania State University, operating as Penn State Milton S. Hershey Medical Center, $682,280 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the mechanisms underlying sleep disturbances in cerebellar dysfunction. The research expands preliminary investigations into cerebellar Purkinje cell activity and rapid-eye-movement (REM) sleep regulation. The project will test whether cerebellar...
- The National Heart, Lung, and Blood Institute awarded Pennsylvania State University (Penn State Milton S. Hershey Medical Center) $178,092 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of surfactant protein A and receptor SP-R210 signaling in bronchopulmonary dysplasia. The research addresses the pathogenesis of bronchopulmonary dysplasia (BPD), a significant respiratory cause affecting more than 15,000 premature infants...
- Federal Grant Award Summary The University of Pennsylvania received a $169,020 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 19, 2025, with completion targeted for August 31, 2027. This research project focuses on decoding nuclear mechanosignaling and epigenetic mediators of mechanical memory in cardiomyocytes—the process by which cardiac cells convert external mechanical signals into...
- The National Heart, Lung, and Blood Institute awarded The Trustees of the University of Pennsylvania $726,531 on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to identify mechanisms of lipid nanoparticle-associated inflammation and reengineer lipid nanoparticles to be non-inflammatory. Lipid nanoparticles have dosed more than one billion patients and enabled delivery of RNA encoding therapeutic proteins for cancer and genetic diseases, but their clinical...
- The National Institute of General Medical Sciences awarded Pennsylvania State University operating as Penn State Milton S. Hershey Medical Center $410,773 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate mitochondria-lysosome crosstalk in health and disease. The research addresses how direct inter-communication between mitochondria and lysosomes affects cellular function and disease. The project examines how membrane contact sites...
- The Department of Health and Human Services National Institutes of Health Office of the Director awarded The Pennsylvania State University $150,594 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate customizable, feasible, and cost-effective dietary assessment methods for infants. The project will pilot and validate three novel infant-tailored dietary assessment methods designed to inform future clinical trials examining early-life...